Hepatocellular carcinoma (HCC) is the third-leading cause of cancer-related death worldwide.

肝细胞癌(HCC)是全球癌症相关死亡的第三大原因。
 

Unlike most solid cancers, future incidence and mortality rates for HCC were projected to largely increase in several regions around the world over the next several years, mostly as a result of the dissemination of hepatitis C virus infection.

与大多数实体癌不同，HCC未来的发病率和死亡率预计在未来几年在世界几个地区大幅增加，主要是由于丙型肝炎病毒感染的传播。
 

Despite the widespread implementation of surveillance programs of at-risk populations, the majority of patients with HCC are diagnosed late, when curative treatments—including liver transplantation, hepatic resection, and image-guided ablation—cannot be applied.

尽管高危人群的监测项目广泛实施，但大多数HCC患者诊断较晚，使包括肝移植、肝切除和图像引导消融在内的治疗方法不能应用。

 

The data collected in the Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib, the largest global observational study completed in the field of HCC so far, suggests that nearly half of all HCC patients receive TACE at some time point in the course of the disease.

全球收集的数据调查治疗肝细胞癌及其索拉菲治疗，这是HCC迄今为止最大的全球观察研究，其表明近一半的HCC患者在疾病的过程中在某个时间点接受TACE。

The evidence supporting the use of lipiodol TACE in the treatment of HCC comes from two meta-analyses including randomized, controlled trials (RCTs) of arterial embolization or chemoembolization versus conservative management.

支持使用碘油TACE治疗HCC的证据来自两项荟萃分析，包括动脉栓塞或化疗栓塞与保守治疗的随机、对照试验(RCT)。
 

These meta-analyses identified a distinct survival benefit for lipiodol TACE with cisplatin or doxorubicin compared to best supportive care.

这些荟萃分析确定，与最佳支持性治疗相比，顺铂或阿霉素对碘油TACE具有明显的生存益处。
 

As a result, Lipiodol TACE has been recommended as the standard of care for the treatment of unresectable, large, or multinodular noninvasive tumors isolated to the liver in patients who have neither evidence of hepatic decompensation nor cancer-related symptoms, that is, those cases classified as intermediate stage according to the Barcelona Clinic for Liver Cancer (BCLC) staging system.

因此，碘油TACE被推荐为治疗不可切除的、大的、或肝内多结节非侵入性肝癌患者的标准治疗，患者还必须没有肝失代偿的证据或癌症相关症状，即，这些病例根据巴塞罗那肝癌(BCLC)分期分类为中期（B期）。

 

All RCTs comparing lipiodol TACE and best supportive care in the treatment of HCC were performed more than a decade ago.

所有比较碘醇TACE和最佳支持性治疗HCC的随机对照试验都是在十多年前进行的。
 

 Distinct technical advances in the performance of TACE and improved patient selection and management took place since the completion of these studies.

自这些研究完成以来，TACE的性能取得了显著的技术进步，患者的选择和管理也得到了改进。
 

A comprehensive understanding of updated efficacy and safety data of lipiodol TACE in the treatment of HCC is important, especially considering that alternate options for regional hepatic tumor treatment—including arterial embolization with drug-eluting beads and internal radiation with yttrium-90 microspheres—have been proposed and are currently undergoing clinical investigation.

全面了解碘油TACE治疗HCC的更新疗效和安全性数据是重要的，特别是考虑到区域肝肿瘤治疗的替代选择，包括药物洗脱珠动脉栓塞和钇-90微球内放射已经被提出，目前正在进行临床研究。
 

Therefore, Riccardo Lencioni et al performed a systematic literature review of the available evidence on the efficacy and safety of lipiodol TACE in treatment of HCC.

因此，Riccardo Lencioni 等人对碘油TACE治疗HCC的有效性和安全性进行了系统的文献回顾。